FiercePharma

FDA Approves Deltoid Injection Site for Abilify Maintena® (aripiprazole) for extended-release injectable suspension in the Treatment of Schizophrenia

Furthermore, in the second study, multiple injections of Abilify Maintena 400 mg in the deltoid muscle resulted in comparable maximal- and minimal-plasma concentrations and comparable exposures of ...
The Globe and Mail

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or ...

Otsuka America Pharmaceutical, Inc. (Otsuka) and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ABILIFY ASIMTUFII ® (aripiprazole) ...
Stockhouse

Health Canada Approves Otsuka and Lundbeck's ABILIFY MAINTENA® (aripiprazole for prolonged release injectable suspension) Alternative Initiation Regimen

MONTREAL , March 3, 2021 /CNW/ - Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Canada Inc. (Lundbeck) announce that Health Canada issued a Notice of Compliance for an alternative initiation ...
Business Wire

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia and Bipolar I ...

If approved, aripiprazole 2-month ready-to-use (RTU), long-acting injectable (LAI) would be the first 2-month, LAI antipsychotic indicated for both treatment of schizophrenia and the maintenance ...
Healio

FDA approves new injection site for Abilify Maintena to treat schizophrenia

Please provide your email address to receive an email when new articles are posted on . Otsuka Pharmaceutical, Inc. and Lundbeck recently announced the FDA expanded the label of Abilify Maintena for ...
Medscape

FDA Okays Aripiprazole for Acute Schizophrenia Relapse

The US Food and Drug Administration (FDA) has approved a labeling update for the long-acting injectable atypical antipsychotic aripiprazole (Abilify Maintena, Otsuka/Lundbeck) for acute schizophrenia ...
News Medical

Abilify Maintena Pre filled Syringe

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Abilify Maintena? Abilify Maintena contains the ...
Business Wire

FDA Approves Once-Monthly ABILIFY MAINTENA™ (aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...